Robert M Rosa | PubMed Health

PubMed2004

Racial differences in potassium disposal.

BACKGROUND: African Americans appear relatively potassium (K(+))-deficient compared with Caucasian Americans whether on unregulated diets or on diets controlled for K(+) content. METHODS: To determine whether extrarenal K(+) disposal was affected by race, KCl (0.5 mEq/kg in 0.9% saline) was infused over 48 minutes to 12 African American and 12 Caucasian American normotensive, healthy subjects. Identical infusions were administered before and after 10 days of fixed electrolyte intake. In addition to serum K(+), glucose, insulin, renin, and aldosterone were measured in blood, and K(+) and sodium (Na(+)) in urine voided spontaneously during the infusions. Data were analyzed using a two-factor analysis of variance (ANOVA) with repeated measures. RESULTS: Basal serum K(+) did not differ between races (African American 3.97 +/- 0.06 mEq/L and Caucasian American 3.98 +/- 0.05, P= NS). The rise in serum K(+) during the infusion and the area under the curve of serum K(+) over the 3.5 hours of observation were both greater in African American (African American +0.82 +/- 0.07 mEq/L and Caucasian American +0.61 +/- 0.06, P= 0.001; and African American 6.9 +/- 0.5 units and Caucasian American 5.1 +/- 0.6, P= 0.0012). The 10-day period of controlled intake did not abolish these differences. Aldosterone at baseline was lower and insulin was higher in African Americans at the end of the infusion. Urinary K(+), plasma glucose, and renin levels did not differ between African Americans and Caucasian Americans. CONCLUSION: Disposal of an intravenous (iv) K(+) load is decreased in African Americans compared with Caucasian Americans, which may reflect decreased Na(+),K(+)-ATPase activity in African Americans in vivo.

Adolescent↗

PubMed2002

Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients.

OBJECTIVE: To determine the safety and long-term efficacy of immune ablation and autologous hematopoietic stem cell transplantation (HSCT) in severe systemic lupus erythematosus (SLE). METHODS: Fifteen patients with persistently active SLE after intravenous (IV) cyclophosphamide (CYC) therapy underwent HSCT. Stem cells were mobilized with CYC (2.0 gm/m(2)) and granulocyte colony-stimulating factor (5 microg/kg/day). Lymphocytes were depleted from the graft by selection of CD34-positive cells. The conditioning regimen used was CYC (200 mg/kg), antithymocyte globulin (90 mg/kg), and methylprednisolone (3 mg/kg). Outcome was evaluated by the SLE Disease Activity Index (SLEDAI), serum complement levels, serologic features, function of diseased organs, and immunosuppressive medication requirements. RESULTS: Fifteen patients with persistent, severe SLE, 7 of whom were critically ill, were treated. No deaths occurred following treatment. The median followup after HSCT has been 36 months (range 12-66 months). All patients demonstrated a gradual, but marked, improvement. The SLEDAI score has declined to 1 year after HSCT, 10 have discontinued immunosuppressive medications, and the prednisone dosage has been tapered to 15 mg/day in 1. Only 2 patients have demonstrated clinical evidence of recurrence of active lupus. One of these patients currently requires no immunosuppressive medication and has a normal performance status. The other patient is currently receiving IV CYC. CONCLUSION: In patients experiencing the persistence of organ-threatening lupus following standard, aggressive therapy, HSCT may be performed safely, with marked improvement and sustained withdrawal of all immunosuppressive medication for most patients. A phase III randomized trial is warranted to determine the relative efficacy and durability of remission of HSCT compared with standard therapies.

Adolescent↗